Emerging proteomics biomarkers and prostate cancer burden in Africa
PDF | HTML | How to cite
Metrics: PDF 2382 views | HTML 3307 views | ?
Henry A. Adeola1,2, Jonathan M. Blackburn2,3,Timothy R. Rebbeck4 and Luiz F. Zerbini1,2
1 International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa
2 Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
3 Institute of Infectious Disease & Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
4 Harvard T.H. Chan School of Public Health and Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Luiz F. Zerbini, email:
Keywords: proteomics, biomarker, prostate cancer, Africa, mass spectrometer
Received: November 23, 2016 Accepted: February 27, 2017 Published: March 25, 2017
Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.